Clinical trial
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety…
NCT00108836 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00108836 |
|---|---|
| Title | Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder |
| Official title | Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anxiety Disorders |
| Intervention type | Drug |
| Interventions | XBD173 |
| Enrollment | 400 |
| Start date | Mar 1, 2005 |
| Completion | May 1, 2006 |
| First posted | Apr 20, 2005 |
| Last update posted | May 20, 2010 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: